
andrew thompson
@adthompson4
Psychiatrist and Mental Health Researcher. Personal account and views are my own.
ID: 2548291374
05-06-2014 15:18:52
2,2K Tweet
947 Followers
399 Following





Huge thanks to Wellcome Lynsey Bilsland @niallpboyce Prof Miranda Wolpert for the visionary support to get this venture launched. And to Australia’s NHMRC & MRFF for support to sustain & expand it



A new FDA approved schizophrenia treatment by Bristol Myers Squibb (Bristol Myers Squibb) is the first new approach for treating the condition in over 50 years. Lynsey Bilsland, our Head of Mental Health Translation, tells us more about the breakthrough 👇 wellcome.org/news/new-treat…


Around 1 in 300 people worldwide are affected by schizophrenia. Antipsychotic drugs are commonly used to treat the condition, but they don’t work for everyone. Last month, the FDA approved a new drug called Cobenfy from Bristol Myers Squibb– and the impact could be huge. [1/3]

The dataset, of 1245 individuals at ultra-high risk (UHR) of psychosis, has been used in a new Uni of Adelaide study to analyse the transition to psychosis and develop a model for predicting an individual’s risk of this transition. More: bit.ly/3U68YxD


Fantastic results from AvatarTherapy - read the paper see 👇


My short book review for BJPsych Journals on 'Marijuana and Madness' (3rd edn). Edited by Deepak D'Souza, David Castle and Sir Robin Murray. Cambridge University Press. 2023. The British Journal of Psychiatry Royal College of Psychiatrists bit.ly/4fK7tNT






New IDEA Risk-stratified Cohort (IDEA-RiSCo) paper: No prediction without prevention: A global qualitative study of attitudes toward using a prediction tool for risk of developing depression during adolescence - bit.ly/4fIPGX4 @gmhequity @prodiahcpa Institute of Psychiatry, Psychology & Neuroscience ESRC Centre for Society and Mental Health Valeria Mondelli @AnnaViduani
